HIV study: could shots beat pills for reducing hidden virus and inflammation?

NCT ID NCT05303337

Recruiting now Knowledge-focused Sponsor: Hôpital Européen Marseille Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 120 people with HIV who switch to a long-acting injectable treatment or stay on oral pills. Researchers will measure HIV reservoirs, immune activation, and gut bacteria changes over a year. The goal is to see if injectable therapy reduces inflammation and hidden virus better than standard oral regimens.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: long-acting injectable antiretroviral therapy
What this could lead to: If this study shows that injectable treatment reduces HIV reservoirs and inflammation better than oral pills, it could point toward improved long-term health for people with HIV.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly test a new cure or therapy. Results may not lead to changes in care, and differences between groups might be small or unclear.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

Hôpital Européen Marseille
RECRUITING

Marseille, 13003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.